Rheumatoid Arthritis DMARD Intervention and UtilizationStudy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5103 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-10-31

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To systematically collect and document use patterns, effectiveness and safety of DMARD treatments currently used in the management of rheumatoid arthritis. The primary purpose of this study is to estimate the incidence of serious adverse experiences and adverse experiences of interest in patients with rheumatoid arthritis (RA) treated with ENBREL®.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders

NCT00132418

Rheumatoid Arthritis

COMPLETED PHASE4

Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy

NCT00244556

Rheumatoid Arthritis

COMPLETED PHASE4

Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

NCT01313208

Rheumatoid Arthritis

COMPLETED PHASE4

Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis

NCT02346877

Persistence to Enbrel

TERMINATED PHASE4

Enbrel Liquid Immunogenicity Protocol

NCT00249041

Rheumatoid Arthritis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drug

etanercept 50 mg/wk SC

ENBREL®

Intervention Type DRUG

50 mg/wk SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ENBREL®

50 mg/wk SC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fulfillment of the 1987 American Rheumatism Association criteria for RA
* Currently requiring the addition of ENBREL® therapy (to be taken alone or in addition to their current DMARD therapy)

Exclusion Criteria

* Currently or previously enrolled in RADIUS 1
* Currently enrolled in a clinical trial where treatments or patient visits are imposed by a protocol
* Active infections
* Known allergy to ENBREL® or any of its components
* Current treatment with ENBREL®
* Patients who have previously been demonstrated to be intolerant of or refractory to ENBREL® therapy
* Nursing or pregnant women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No